Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella

Imagem de Miniatura
Arquivos
art_FEIO_Organic_effects_of_associating_paclitaxel_with_a_lipidbased_2017.PDF (2.27 MB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Autores
FEIO, Danielle Cristinne Azevedo
OLIVEIRA, Nayara Cristina Lima de
PEREIRA, Edmundo Luis Rodrigues
MUNIZ, Jose Augusto Pereira Carneiro
MONTENEGRO, Raquel Carvalho
ALVES, Ana Paula Negreiros Nunes
LIMA, Patricia Danielle Lima de
BURBANO, Rommel Rodriguez
Citação
INTERNATIONAL JOURNAL OF NANOMEDICINE, v.12, p.3827-3837, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Lipid-based nanoparticle systems have been used as vehicles for chemotherapeutic agents in experimental cancer treatments. Those systems have generally been credited with attenuating the severe toxicity of chemotherapeutic agents. This study aimed to investigate the effects of associating paclitaxel (PTX) with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella, documenting the toxicity as measured by serum biochemistry, which is a detailed analysis of blood and tissue. Eighteen C. apella were studied: three animals were treated with cholesterol-rich nanoemulsion (LDE) only, without PTX, administered intravenously every 3 weeks, during six treatment cycles; six animals were treated with PTX associated with LDE at the same administration scheme, three with lower (175 mg/m(2)) and three with higher (250 mg/m(2)) PTX doses; and six animals were treated with commercial PTX, three with the lower and three with the higher doses. In the LDE-PTX group, no clinical toxicity appeared, and the weight-food consumption curve was similar to that of the controls. Two animals treated with commercial PTX presented weight loss, nausea and vomiting, diarrhea, skin flaking, 70% loss of body hair, and decreased physical activity. The use of LDE as a carrier at both lower and higher doses reduced the toxicity of the drug in this species, which is closely related to human subjects. This was observed not only by clinical, biochemical, and hematological profiles but also by the histopathological analysis. The results of this study support the assumption that lipid-based nanoparticle systems used as drug carriers can serve as valuable tools to decrease the toxicity and increase the safety of chemotherapeutic agents.
Palavras-chave
nanoparticles, LDE, paclitaxel, toxicity, Cebus apella
URI
https://observatorio.fm.usp.br/handle/OPI/21561
Referências
  1. Almeida CP, 2010, INT J NANOMED, V5, P679
  2. Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015
  3. Bertato MP, 2012, CLINICS, V67, P347, DOI 10.6061/clinics/2012(04)08
  4. Bonassa EMA, 2012, ENFERMAGEM TERAPEUTI
  5. Brandao HN, 2010, QUIM NOVA, V33, P1359, DOI 10.1590/S0100-40422010000600026
  6. Calosi P, 2013, INTEGR COMP BIOL, V53, P660, DOI 10.1093/icb/ict041
  7. Cuppari L., 2009, GUIA NUTR NUTR CLIN
  8. Holanda CMDX, 2008, BRAZ ARCH BIOL TECHN, V51, P191, DOI 10.1590/S1516-89132008000700031
  9. Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3
  10. EXTRA JM, 1993, CANCER RES, V53, P1037
  11. Favero GM, 2010, BIOL RES, V43, P439, DOI [/S0716-97602010000400008, 10.4067/S0716-97602010000400008]
  12. FOLCH J, 1957, J BIOL CHEM, V226, P497
  13. Gao L, 2014, COLLOID SURFACE B, V117, P122, DOI 10.1016/j.colsurfb.2014.02.016
  14. Goble S, 2003, SURG CLIN N AM, V83, P943, DOI 10.1016/S0039-6109(03)00071-9
  15. Goncalves RP, 2005, LEUKEMIA RES, V29, P955, DOI 10.1016/j.leukres.2005.01.013
  16. Hamaguchi T, 2005, BRIT J CANCER, V92, P1240, DOI 10.1038/sj.bjc.6602479
  17. Han JJ, 2014, TUMORI, V100, P439, DOI 10.1700/1636.17906
  18. Hirata RDC, 1999, BBA-MOL CELL BIOL L, V1437, P53, DOI 10.1016/S1388-1981(98)00004-3
  19. Hoffbrand AV, 2013, FUNDAMENTOS HEMATOLO
  20. Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y
  21. Kapse-Mistry S, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00159
  22. Kim C, 2005, KIDNEY INT, V67, P1028, DOI 10.1111/j.1523-1755.2005.00166.x
  23. Kratz F, 2012, J CONTROL RELEASE, V161, P429, DOI 10.1016/j.jconrel.2011.11.028
  24. Lima MF, 2009, 2009 INT NUCL ATL C
  25. Liu GX, 2014, INT J MOL SCI, V15, P15287, DOI 10.3390/ijms150915287
  26. Ma P., 2013, J NANOMED NANOTECHNO, V4, DOI 10.4172/2157-7439.1000164
  27. Macdougall IC, 2002, NEPHROL DIAL TRANSPL, V17, P39
  28. Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051
  29. MARANHAO RC, 1994, CANCER RES, V54, P4660
  30. MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988
  31. Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3
  32. MARANHAO RC, 1992, BRAZ J MED BIOL RES, V25, P1003
  33. Nakamura T, 2015, INT J UROL, V22, P288, DOI 10.1111/iju.12665
  34. Narang AS, 2009, PHARMACEUTICAL PERSPECTIVES OF CANCER THERAPEUTICS, P49, DOI 10.1007/978-1-4419-0131-6_2
  35. Naves Elisete de Araujo, 2006, Bioscience Journal, V22, P125
  36. NESTEL PJ, 1982, NEW ENGL J MED, V307, P329, DOI 10.1056/NEJM198208053070601
  37. Oliveira Elizabeth M., 2013, PACKAGE LEAFLET
  38. Panis C, 2012, CANCER IMMUNOL IMMUN, V61, P481, DOI 10.1007/s00262-011-1117-0
  39. Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8
  40. Riviello MC, 2001, J MED PRIMATOL, V30, P308, DOI 10.1034/j.1600-0684.2001.300604.x
  41. Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y
  42. RON D, 1983, ATHEROSCLEROSIS, V46, P67, DOI 10.1016/0021-9150(83)90165-X
  43. Schwartz J, 2005, ANN ONCOL, V16, P247, DOI 10.1093/annonc/mdi058
  44. Siau C, 2006, EXP NEUROL, V201, P507, DOI 10.1016/j.expneurol.2006.05.007
  45. SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002
  46. Takayama S, 2008, P JPN ACAD B-PHYS, V84, P176, DOI 10.2183/pjab.84.176
  47. ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005
  48. Wang Y, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/854872
  49. Wirz A, 2008, AM J PRIMATOL, V70, P463, DOI 10.1002/ajp.20520
  50. Woo HL, 1996, AM J CLIN ONCOL-CANC, V19, P290, DOI 10.1097/00000421-199606000-00016
  51. Yamauchi H, 2013, CIRCULATION, V128, pS263, DOI 10.1161/CIRCULATIONAHA.112.000396
  52. Yu B, 2010, MOL MEMBR BIOL, V27, P286, DOI 10.3109/09687688.2010.521200

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03